Artielle

Artielle is a biotechnology company focused on developing innovative biologic drugs that address inflammatory and degenerative diseases, aiming to enhance patient quality of life through advanced therapeutic solutions. Founded in 2004 and headquartered in San Mateo, US, Artielle is dedicated to the development of biologic treatments with a focus on neuroinflammatory and degenerative diseases. The company has engaged in five deals, with its most recent funding round being a Venture Debt of USD 0. 1 mn raised on September 9, 2010, totaling USD 0.

71 mn raised. John Metcalf serves as the CEO, leading the company through its strategic initiatives. Artielle ImmunoTherapeutics specializes in creating a pioneering platform of biologic drugs aimed at treating various inflammatory and degenerative diseases. The company targets neuroinflammatory conditions, including multiple sclerosis, optic neuritis, and methamphetamine addiction, while also addressing degenerative diseases such as stroke.

The platform has potential applications in rheumatoid arthritis, uveitis, age-related macular degeneration, and celiac disease, primarily serving markets in North America and Europe. Artielle ImmunoTherapeutics generates revenue through strategic partnerships and collaborations with healthcare providers and research institutions. The company engages in business-to-business transactions that grant access to its biologic drug products, which are crucial in managing severe inflammatory and degenerative diseases. Revenue streams may include licensing agreements for its proprietary technologies, structured to facilitate growth while ensuring healthcare institutions can access these therapies.

Artielle plans to utilize recent funding of USD 0. 1 mn raised in September 2010 to support the ongoing development of new therapeutic products aimed at addressing diverse inflammatory diseases. The company is focused on expanding its market presence in North America and Europe, with ambitions to introduce additional innovative biologic therapies that target chronic and acute conditions by 2015.